Compare ORIC & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIC | CDNA |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | United States | United States |
| Employees | 111 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2020 | 2007 |
| Metric | ORIC | CDNA |
|---|---|---|
| Price | $13.74 | $50.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $19.73 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.67 | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $22.30 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $7.23 | $12.37 |
| 52 Week High | $14.93 | $49.76 |
| Indicator | ORIC | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.75 | 68.55 |
| Support Level | $13.12 | $44.80 |
| Resistance Level | $13.97 | $49.76 |
| Average True Range (ATR) | 0.63 | 1.78 |
| MACD | -0.07 | -0.39 |
| Stochastic Oscillator | 52.96 | 89.88 |
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.